因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

六月节休市 06-18 16:00:00 EDT

98.22

-0.77

-0.78%

盘后99.00

+0.78+0.79%

19:55 EDT

最高99.62	最低96.09	成交量405.86万
今开99.58	昨收98.99	日振幅3.57%
总市值195.47亿	流通市值160.14亿	总股本1.99亿
成交额3.98亿	换手率2.49%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":98.22,"timestamp":1781812800000,"preClose":98.99,"halted":0,"volume":4058615,"hourTrading":{"tag":"盘后","latestPrice":99,"preClose":98.22,"latestTime":"19:55 EDT","volume":414685,"amount":40727244.234096,"timestamp":1781826947243,"change":0.78,"changeRate":0.007941,"amplitude":0.018123},"delay":0,"changeRate":-0.007778563491261704,"floatShares":163042517,"shares":199014486,"eps":7.08,"marketStatus":"六月节休市","change":-0.77,"latestTime":"06-18 16:00:00 EDT","open":99.58,"high":99.62,"low":96.09,"amount":397761397.3553,"amplitude":0.03566,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.08,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":98.99,"preHourTrading":{"tag":"盘前","latestPrice":99.26,"preClose":98.99,"latestTime":"09:29 EDT","volume":1278,"amount":126738.09702,"timestamp":1781789399999,"change":0.27,"changeRate":0.002728,"amplitude":0.028791},"postHourTrading":{"tag":"盘后","latestPrice":99,"preClose":98.22,"latestTime":"19:55 EDT","volume":414685,"amount":40727244.234096,"timestamp":1781826947243,"change":0.78,"changeRate":0.007941,"amplitude":0.018123},"volumeRatio":2.0508795750406605,"impliedVol":0.3154,"impliedVolPercentile":0.2629},"requestUrl":"/m/hq/s/INCY/tweets","defaultTab":"tweets","newsList":[{"id":"1125254391","title":"因塞特医疗日本公司宣布Minjuvi®（Tafasitamab）联合来那度胺获准用于治疗复发或难治性弥漫性大B细胞淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1125254391","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125254391?lang=zh_cn&edition=full","pubTime":"2026-06-19 14:00","pubTimestamp":1781848817,"startTime":"0","endTime":"0","summary":"因塞特医疗的日本子公司宣布，其药物Minjuvi®（通用名：Tafasitamab）联合来那度胺的治疗方案，已获得监管批准，用于治疗复发或难治性弥漫性大B细胞淋巴瘤的成年患者。该疗法为这一特定患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4550","BK4139","INCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174266617","title":"Mirum制药与因塞特医疗公布Zilurgisertib治疗进行性骨化性纤维发育不良的关键2期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174266617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174266617?lang=zh_cn&edition=full","pubTime":"2026-06-15 04:36","pubTimestamp":1781469383,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 与因塞特医疗联合宣布，其候选药物Zilurgisertib在治疗进行性骨化性纤维发育不良的关键性2期PROGRESS研究中，取得了积极的顶线结果。与安慰剂相比，接受Zilurgisertib治疗的患者在关键疾病活动指标上表现出显著改善。安全性方面，Zilurgisertib的耐受性普遍良好，观察到的不良事件与先前研究数据一致。此次积极数据标志着在治疗这种罕见、致残性遗传疾病方面的一个重要进展。两家公司正与监管机构讨论下一步开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","INCY","MIRM","BK4532","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175927260","title":"因塞特医疗在EHA 2026公布新阳性数据：INCA033989在骨髓纤维化和原发性血小板增多症患者中实现快速、强劲且持久的临床与分子应答，耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1175927260","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175927260?lang=zh_cn&edition=full","pubTime":"2026-06-13 23:16","pubTimestamp":1781363775,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，在欧洲血液学协会2026年大会上公布的最新积极数据显示，其候选药物INCA033989在治疗骨髓纤维化与原发性血小板增多症患者时，展现出快速、强劲且持久的临床及分子应答，同时表现出良好的耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4585","BK4139","BK4550","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101824689","title":"因塞特医疗关键三期FRONTMIND试验数据公布：Tafasitamab组合疗法在2026年EHA大会上展示延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1101824689","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101824689?lang=zh_cn&edition=full","pubTime":"2026-06-13 18:01","pubTimestamp":1781344876,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）在2026年欧洲血液学协会（EHA）大会全体会议上公布了其关键性三期FRONTMIND试验的结果。数据显示，tafasitamab（商品名：Monjuvi®/Minjuvi®）联合治疗方案显著延长了患者的无进展生存期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4585","BK4550","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194333066","title":"因塞特医疗将收购星疗法旗下全资子公司维加疗法，拓展其血液学版图至出血性疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1194333066","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194333066?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:02","pubTimestamp":1780916524,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，将收购星疗法旗下的全资子公司维加疗法。此项交易旨在拓展因塞特在血液学领域的产品组合，正式进军出血性疾病治疗市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4550","BK4139","INCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117430155","title":"异动解读｜因塞特医疗盘中上涨5.89%，关键临床试验数据积极提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1117430155","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117430155?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:15","pubTimestamp":1780503310,"startTime":"0","endTime":"0","summary":"6月3日，因塞特医疗盘中上涨5.89%，报97.775美元/股，成交额7680.94万美元。消息面上，因塞特医疗近日宣布其关键的Frontmind临床试验数据表明，Tafasitamab联合治疗方案能够显著延长患者的无进展生存期。因塞特医疗是一家全球生物制药公司，从事专有疗法的发现、开发和商业化，研究和商业努力集中在血液学、肿瘤学、炎症和自身免疫三个治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144835206","title":"因塞特医疗：关键Frontmind试验显示Tafasitamab联合疗法显著延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1144835206","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144835206?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:08","pubTimestamp":1780142897,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其关键的Frontmind临床试验数据表明，Tafasitamab（商品名Monjuvi®/Minjuvi®）联合治疗方案能够显著延长患者的无进展生存期。这一积极结果凸显了该疗法在相关治疗领域的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","BK4139","BK4550","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165248541","title":"因塞特医疗与爱迪生科学宣布战略合作，将启用Kosmos AI平台赋能研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1165248541","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165248541?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:08","pubTimestamp":1779192523,"startTime":"0","endTime":"0","summary":"因塞特医疗与爱迪生科学公司已共同宣布达成一项战略合作。双方将启用Kosmos人工智能平台，以加速并深化其在生物医药领域的研究与开发工作。\n此次合作旨在整合前沿的人工智能技术，探索新的科学发现路径。通过利用Kosmos平台强大的数据处理与分析能力，两家公司期望能够更高效地识别潜在的治疗靶点，优化候选药物分子设计，并最终推动创新疗法的开发进程。\n战略联盟的建立，标志着双方在利用数字化工具驱动研发创新方面迈出了关键一步。这一举措不仅有望缩短药物研发周期，也可能为应对复杂疾病带来新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4532","BK4139","BK4550","BK4588","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169983668","title":"因塞特医疗宣布超过20篇摘要获选于2026年欧洲血液学协会大会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1169983668","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169983668?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:31","pubTimestamp":1778592686,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其超过20篇研究摘要已获选在即将举行的2026年欧洲血液学协会大会上进行展示。这一成果突显了公司在血液学领域的持续研究投入与科学贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4139","BK4550","BK4585","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194577649","title":"因塞特医疗Opzelura耐受性良好：24周内仅1.7%用药部位反应且无新增安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1194577649","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194577649?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:51","pubTimestamp":1778158306,"startTime":"0","endTime":"0","summary":"因塞特医疗旗下药物Opzelura在长达24周的临床观察中展现出卓越的安全性表现。数据显示，该药物引发的用药部位反应率仅为1.7%，且未出现新的安全性风险信号。\n研究人员指出，这一结果进一步验证了Opzelura在长期用药场景下的可靠性与安全性。极低的局部反应发生率结合零新增安全信号的特性，为慢性疾病患者提供了重要的临床用药依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4532","INCY","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108490356","title":"因塞特公布Opzelura乳膏治疗中重度特应性皮炎三期试验24周长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1108490356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108490356?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:51","pubTimestamp":1778158277,"startTime":"0","endTime":"0","summary":"生物制药公司因塞特医疗近日公布了其研发的Opzelura®（芦可替尼）乳膏在三期临床试验TRUE-AD4中取得的24周长期疗效数据。该研究针对中重度特应性皮炎成人患者展开系统性评估。\n试验结果显示，持续使用Opzelura乳膏治疗24周的患者群体呈现出显著且持久的临床症状改善。数据分析表明，该局部治疗药物在延长治疗周期下仍保持稳定的安全性和耐受性特征。\n此次公布的长期数据为芦可替尼乳膏在慢性皮肤病治疗领域的应用提供了更充分的循证医学依据。研究人员指出，这些发现将有助于优化中重度特应性皮炎患者的长期治疗策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","INCY","BK4532","BK4550","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108170491","title":"因塞特医疗：芦可替尼乳膏欧盟II类变更申请获数据支持，反馈预期2026年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1108170491","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108170491?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:51","pubTimestamp":1778158276,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）宣布，其芦可替尼乳膏在欧盟的II类变更申请已获得最新数据支持。公司预计将于2026年上半年获得监管机构的反馈意见。\n此次申报进展标志着该药物在欧盟市场拓展的重要里程碑。临床数据将为申请提供关键依据，助力乳膏剂型在欧盟地区的审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4550","BK4588","INCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152839112","title":"因塞特医疗Jakafi XR新药即将迎来关键节点 美国监管决定与中期商业上市计划浮出水面","url":"https://stock-news.laohu8.com/highlight/detail?id=1152839112","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152839112?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:07","pubTimestamp":1777374434,"startTime":"0","endTime":"0","summary":"因塞特医疗旗下备受关注的Jakafi XR（鲁索利替尼）缓释片剂迎来重要进展。该公司预期将在2026年中期获得美国监管机构的审评结果，并有望同期启动该药物的商业化上市进程。\n这一时间节点的明确为血液疾病治疗领域注入新的期待。若获批，Jakafi XR将成为因塞特医疗产品管线中的重要延伸，为患者提供更便捷的用药选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4532","BK4585","BK4139","BK4588","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138548835","title":"财报前瞻｜因塞特医疗本季度营收预计同比增22.99%，机构多持积极态度","url":"https://stock-news.laohu8.com/highlight/detail?id=1138548835","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138548835?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:56","pubTimestamp":1776700611,"startTime":"0","endTime":"0","summary":"因塞特医疗将于2026年04月27日发布最新季度财报，市场普遍预期收入与盈利维持同比增长，费用端和产品结构变化将影响利润弹性。上季度公司实现营收15.07亿美元，同比增长27.84%；毛利率51.38%；归属于母公司股东的净利润为2.99亿美元，净利率19.86%；调整后每股收益为1.80美元，同比增长25.87%。多家机构聚焦于本季度收入同比增22.99%、调整后每股收益同比增37.37%的共识路径，并强调产品组合驱动的毛利率稳定与EBIT高增可持续性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜因塞特医疗本季度营收预计同比增22.99%，机构多持积极态度","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184093165","title":"Adagene与Incyte达成临床合作，评估Muzastotug (Adg126)联合Incyte的TgfßR2xPD-1双特异性抗体(Inca33890)用于微卫星稳定结直肠癌(MSS CRC)患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1184093165","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184093165?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:02","pubTimestamp":1775127720,"startTime":"0","endTime":"0","summary":"Adagene宣布与Incyte达成临床合作，将共同评估Muzastotug (Adg126)与Incyte的TgfßR2xPD-1双特异性抗体(Inca33890)联合疗法在微卫星稳定结直肠癌(MSS CRC)患者中的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4585","BK4550","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101340266","title":"因塞特医疗：Povorcitinib 54周总体安全性特征与既往数据一致，45毫克与75毫克剂量均耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1101340266","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101340266?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:00","pubTimestamp":1774724430,"startTime":"0","endTime":"0","summary":"因塞特医疗公布的研究数据显示，Povorcitinib在长达54周的治疗期内，其总体安全性特征与先前报告的结果保持一致。无论是每日45毫克还是75毫克的给药剂量，均表现出良好的耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","BK4550","BK4588","INCY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131957399","title":"因塞特医疗：Povorcitinib治疗在关键炎症性皮损类型中实现持续改善，高达20%患者达到完全消退","url":"https://stock-news.laohu8.com/highlight/detail?id=1131957399","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131957399?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:00","pubTimestamp":1774724427,"startTime":"0","endTime":"0","summary":"因塞特医疗公布的研究数据显示，其候选药物Povorcitinib在针对多种关键炎症性皮损类型的治疗中展现出持续性的消退效果。值得注意的是，临床试验结果揭示，接受该治疗方案的患者群体中，实现皮损完全消退的比例最高可达20%。\n该研究通过系统评估不同形态的炎症性皮损变化，证实Povorcitinib能够同步改善各类关键病灶指标。分析指出，这种广谱疗效特征为患者提供了更全面的治疗选择，特别是对于复杂炎症性皮肤疾病的长期管理具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4139","INCY","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148003962","title":"骑士制药宣布Minjuvi®（Tafasitamab）在巴西获批新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1148003962","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148003962?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:32","pubTimestamp":1773747171,"startTime":"0","endTime":"0","summary":"骑士制药宣布，其产品Minjuvi®（Tafasitamab）在巴西监管机构批准下新增一项适应症。此次获批标志着该药物在巴西市场的应用范围进一步扩大，为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","INCY","BK4532","BK4585","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130476791","title":"Knight Therapeutics宣布在阿根廷和墨西哥提交Minjuvi®（Tafasitamab）用于滤泡性淋巴瘤的补充监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1130476791","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130476791?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:31","pubTimestamp":1773747074,"startTime":"0","endTime":"0","summary":"Knight Therapeutics公司已正式向阿根廷和墨西哥的药品监管机构提交了Minjuvi®（Tafasitamab）用于治疗滤泡性淋巴瘤的补充注册申请。这一进展标志着该药物在拓展拉丁美洲市场方面迈出关键一步，为当地患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4550","BK4588","INCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","NVOX","BK4530","BK4532","BK4599","IE00BFMHRM44.USD","LU0757428866.USD","LU0029874061.USD","NVOH","LU1815336091.USD","REGN","BK4588","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","LU0128526141.USD","IE00BZ1G4Q59.USD","BK4121","AZN","NVO","LU0390134368.USD","BK4007","LU0154236417.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com;investor.incyte.com","stockEarnings":[{"period":"1week","weight":-0.0891},{"period":"1month","weight":0.0274},{"period":"3month","weight":0.082},{"period":"6month","weight":-0.0435},{"period":"1year","weight":0.4387},{"period":"ytd","weight":-0.0056}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司，从事专有疗法的发现、开发和商业化。其研究和商业努力集中在三个治疗领域：血液学、肿瘤学、炎症和自身免疫。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.084187},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.001443},{"month":3,"riseRate":0.424242,"avgChangeRate":-0.039602},{"month":4,"riseRate":0.484848,"avgChangeRate":-0.010488},{"month":5,"riseRate":0.636364,"avgChangeRate":0.060447},{"month":6,"riseRate":0.606061,"avgChangeRate":0.023895},{"month":7,"riseRate":0.53125,"avgChangeRate":0.01586},{"month":8,"riseRate":0.53125,"avgChangeRate":0.019237},{"month":9,"riseRate":0.40625,"avgChangeRate":-0.019519},{"month":10,"riseRate":0.53125,"avgChangeRate":0.026823},{"month":11,"riseRate":0.59375,"avgChangeRate":0.061387},{"month":12,"riseRate":0.59375,"avgChangeRate":0.093713}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}